Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

NCT00002900 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This clinical trial is studying the effect of chemotherapy on heart function in treating women who have breast cancer with negative axillary lymph nodes and who are undergoing treatment on the SWOG-8897 clinical trial.

Interventions

  • PROCEDURE management of therapy complications

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center — Duarte
  • Veterans Affairs Medical Center - Long Beach — Long Beach
  • USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles
  • Veterans Affairs Medical Center - West Los Angeles — Los Angeles
  • Jonsson Comprehensive Cancer Center, UCLA — Los Angeles
  • Veterans Affairs Outpatient Clinic - Martinez — Martinez
  • CCOP - Bay Area Tumor Institute — Oakland
  • Chao Family Comprehensive Cancer Center — Orange
  • University of California Davis Cancer Center — Sacramento
  • UCSF Comprehensive Cancer Center — San Francisco
  • CCOP - Santa Rosa Memorial Hospital — Santa Rosa
  • David Grant Medical Center — Travis Air Force Base

Arizona

  • CCOP - Western Regional, Arizona — Phoenix
  • Veterans Affairs Medical Center - Phoenix (Carl T. Hayden) — Phoenix
  • Veterans Affairs Medical Center - Tucson — Tucson
  • Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson

Arkansas

  • University of Arkansas for Medical Sciences — Little Rock
  • Veterans Affairs Medical Center - Little Rock (McClellan) — Little Rock

Alabama

  • MBCCOP - Gulf Coast — Mobile

Colorado

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center — Denver

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 1997-02

Sponsor

SWOG Cancer Research Network

212 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002900

The ClinicalTrials.gov registry entry for NCT00002900 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which management of therapy complications is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00002900 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Arizona, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00002900 about?

NCT00002900 is a clinical study titled "SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This clinical trial is studying the effect of chemotherapy on heart function in treating women who have breast cancer with negative axillary lymph nodes and who are under...

What is the current status of trial NCT00002900?

This trial is currently completed. The enrollment target is 180 participants. The study started on 1997-02.

What conditions does trial NCT00002900 study?

This clinical trial studies the following conditions: Breast Cancer, Cardiac Toxicity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00002900?

The interventions under investigation include: management of therapy complications (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00002900?

This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00002900 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial